Sign In
Buy VRTX
$441.74
+13.40 (+3.13%)
At Close: Jun 04, 2026
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
01:00pm, Friday, 25'th Oct 2024
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous neph
The Smartest Growth Stock to Buy With $500 Right Now
05:45am, Friday, 25'th Oct 2024
This stock might not be available for under $500 for long.
Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits
09:15am, Thursday, 24'th Oct 2024
Its latest report of clinical data suggests it has a winner on its hands.
BMY or VRTX: Which Is the Better Value Stock Right Now?
12:46pm, Tuesday, 22'nd Oct 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers v
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
10:06am, Tuesday, 22'nd Oct 2024
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today
07:06pm, Monday, 21'st Oct 2024
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $478.09, denoting a -1.02% change from the preceding trading day.
Vertex Pharmaceuticals: A Long-Term Growth Monster
03:23am, Monday, 21'st Oct 2024
Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown gre
Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030
09:15am, Saturday, 19'th Oct 2024
There's no need to change a winning formula.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly sele
Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
04:09am, Friday, 18'th Oct 2024
Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex treatment pr
Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to Note
07:06pm, Monday, 14'th Oct 2024
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $484.94, moving +0.67% from the previous trading session.
Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever
09:00am, Sunday, 13'th Oct 2024
These profitable companies are facing long-term growth runways.
3 No-Brainer Growth Stocks to Buy in October
07:15am, Sunday, 13'th Oct 2024
These stocks look like slam-dunk picks for growth investors.
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
08:00am, Friday, 11'th Oct 2024
None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
04:05pm, Thursday, 10'th Oct 2024
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The comp
